{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T18:17:00Z","timestamp":1785521820988,"version":"3.56.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T00:00:00Z","timestamp":1775779200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T00:00:00Z","timestamp":1775779200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82473296"],"award-info":[{"award-number":["82473296"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cancer Res Clin Oncol"],"DOI":"10.1007\/s00432-026-06470-4","type":"journal-article","created":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T14:35:54Z","timestamp":1775831754000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["The efficacy and toxicity of TRT on metastatic NSCLC in patients treated with targeted therapy and chemoimmunotherapy"],"prefix":"10.1007","volume":"152","author":[{"given":"Lishan","family":"Xue","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinquan","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuxin","family":"Geng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ning","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feifei","family":"Teng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,10]]},"reference":[{"issue":"6","key":"6470_CR1","volume":"14","author":"M Aiad","year":"2022","unstructured":"Aiad M, Fresco K, Prenatt Z, Tahir A, Ramos-Feliciano K, Stoltzfus J et al (2022) Comparison of pneumonitis rates and severity in patients with lung cancer treated by immunotherapy, radiotherapy, and immunoradiotherapy. Cureus 14(6):e25665","journal-title":"Cureus"},{"issue":"20","key":"6470_CR2","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.1056\/NEJMoa1709937","volume":"377","author":"SJ Antonia","year":"2017","unstructured":"Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R et al (2017) Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer. N Engl J Med 377(20):1919\u20131929","journal-title":"N Engl J Med"},{"issue":"24","key":"6470_CR3","doi-asserted-by":"publisher","first-page":"2342","DOI":"10.1056\/NEJMoa1809697","volume":"379","author":"SJ Antonia","year":"2018","unstructured":"Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R et al (2018) Overall survival with Durvalumab after chemoradiotherapy in Stage III NSCLC. N Engl J Med 379(24):2342\u20132350","journal-title":"N Engl J Med"},{"issue":"2","key":"6470_CR4","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/j.jtho.2020.11.002","volume":"16","author":"K Banfill","year":"2021","unstructured":"Banfill K, Giuliani M, Aznar M, Franks K, McWilliam A, Schmitt M et al (2021) Cardiac toxicity of thoracic radiotherapy: Existing evidence and future directions. J Thorac Oncol 16(2):216\u2013227","journal-title":"J Thorac Oncol"},{"issue":"17","key":"6470_CR5","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1056\/NEJMoa1507643","volume":"373","author":"H Borghaei","year":"2015","unstructured":"Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE et al (2015) Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med 373(17):1627\u20131639","journal-title":"N Engl J Med"},{"key":"6470_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2023.102545","volume":"116","author":"A Desai","year":"2023","unstructured":"Desai A, Peters S (2023) Immunotherapy-based combinations in metastatic NSCLC. Cancer Treat Rev 116:102545","journal-title":"Cancer Treat Rev"},{"issue":"10030","key":"6470_CR7","doi-asserted-by":"publisher","first-page":"1837","DOI":"10.1016\/S0140-6736(16)00587-0","volume":"387","author":"L Fehrenbacher","year":"2016","unstructured":"Fehrenbacher L, Spira A, Ballinger M, Kowanetz M, Vansteenkiste J, Mazieres J et al (2016) Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial. Lancet (London, England) 387(10030):1837\u20131846","journal-title":"Lancet (London, England)"},{"issue":"28","key":"6470_CR8","doi-asserted-by":"publisher","first-page":"2518","DOI":"10.1200\/JCO.19.00934","volume":"37","author":"EB Garon","year":"2019","unstructured":"Garon EB, Hellmann MD, Rizvi NA, Carcereny E, Leighl NB, Ahn MJ et al (2019) Five-year overall survival for patients with advanced Non\u2012Small-Cell Lung Cancer treated with Pembrolizumab: results from the Phase I KEYNOTE-001 study. J Clin Oncol 37(28):2518\u20132527","journal-title":"J Clin Oncol"},{"issue":"9","key":"6470_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1001\/jamaoncol.2021.2301","volume":"7","author":"SK Jabbour","year":"2021","unstructured":"Jabbour SK, Lee KH, Frost N, Breder V, Kowalski DM, Pollock T et al (2021) Pembrolizumab plus concurrent chemoradiation therapy in patients with unresectable, locally advanced, stage III non-small cell lung cancer: the phase 2 KEYNOTE-799 nonrandomized trial. JAMA Oncol 7(9):1\u20139","journal-title":"JAMA Oncol"},{"key":"6470_CR10","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.lungcan.2020.05.035","volume":"146","author":"HA Jung","year":"2020","unstructured":"Jung HA, Noh JM, Sun JM, Lee SH, Ahn JS, Ahn MJ et al (2020) Real world data of Durvalumab consolidation after chemoradiotherapy in Stage III non-small-cell lung cancer. Lung Cancer 146:23\u201329","journal-title":"Lung Cancer"},{"key":"6470_CR11","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1016\/j.ejphar.2018.07.034","volume":"834","author":"YT Lee","year":"2018","unstructured":"Lee YT, Tan YJ, Oon CE (2018) Molecular targeted therapy: treating cancer with specificity. Eur J Pharmacol 834:188\u2013196","journal-title":"Eur J Pharmacol"},{"key":"6470_CR12","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.863461","volume":"12","author":"L Peng","year":"2022","unstructured":"Peng L, Zhu L, Sun Y, Stebbing J, Selvaggi G, Zhang Y et al (2022) Targeting ALK rearrangements in NSCLC: current state of the art. Front Oncol 12:863461","journal-title":"Front Oncol"},{"key":"6470_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2023.109681","volume":"184","author":"P Peng","year":"2023","unstructured":"Peng P, Gong J, Zhang Y, Zhou S, Li Y, Han G et al (2023) EGFR-TKIs plus stereotactic body radiation therapy (SBRT) for Stage IV non-small cell lung cancer (NSCLC): a prospective, multicenter, randomized, controlled Phase II study. Radiother Oncol 184:109681","journal-title":"Radiother Oncol"},{"issue":"19","key":"6470_CR14","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","volume":"375","author":"M Reck","year":"2016","unstructured":"Reck M, Rodr\u00edguez-Abreu D, Robinson AG, Hui R, Cs\u0151szi T, F\u00fcl\u00f6p A et al (2016) Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med 375(19):1823\u20131833","journal-title":"N Engl J Med"},{"issue":"suppl_1","key":"6470_CR15","doi-asserted-by":"publisher","first-page":"i20","DOI":"10.1093\/annonc\/mdx704","volume":"29","author":"J Remon","year":"2018","unstructured":"Remon J, Steuer CE, Ramalingam SS, Felip E (2018) Osimertinib and other third-generation EGFR TKI in EGFR-mutant NSCLC patients. Ann Oncol 29(suppl_1):i20\u2013i27","journal-title":"Ann Oncol"},{"issue":"1","key":"6470_CR16","first-page":"7","volume":"71","author":"RL Siegel","year":"2021","unstructured":"Siegel RL, Miller KD, Fuchs HE, Jemal A (2021) Cancer statistics, 2021. CA Cancer J Clin 71(1):7\u201333","journal-title":"CA Cancer J Clin"},{"issue":"2","key":"6470_CR17","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1056\/NEJMoa1713137","volume":"378","author":"JC Soria","year":"2018","unstructured":"Soria JC, Ohe Y, Vansteenkiste J, Reungwetwattana T, Chewaskulyong B, Lee KH et al (2018) Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. N Engl J Med 378(2):113\u2013125","journal-title":"N Engl J Med"},{"key":"6470_CR18","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.934110","volume":"12","author":"C Sun","year":"2022","unstructured":"Sun C, Wang S, Ye W, Wang R, Tan M, Zhang H et al (2022) The prognostic value of tumor size, volume and tumor volume reduction rate during concurrent chemoradiotherapy in patients with cervical cancer. Front Oncol 12:934110","journal-title":"Front Oncol"},{"key":"6470_CR19","doi-asserted-by":"publisher","DOI":"10.3390\/cells11030320","author":"S Tang","year":"2022","unstructured":"Tang S, Qin C, Hu H, Liu T, He Y, Guo H et al (2022) Immune checkpoint inhibitors in non-small cell lung cancer: progress, challenges, and prospects. Cells. https:\/\/doi.org\/10.3390\/cells11030320","journal-title":"Cells"},{"issue":"1","key":"6470_CR20","doi-asserted-by":"publisher","first-page":"77","DOI":"10.3892\/or.2020.7593","volume":"41","author":"N Wang","year":"2019","unstructured":"Wang N, Wang L, Meng X, Wang J, Zhu L, Liu C et al (2019) Osimertinib (AZD9291) increases radio-sensitivity in EGFR T790M non-small cell lung cancer. Oncol Rep 41(1):77\u201386","journal-title":"Oncol Rep"},{"issue":"5","key":"6470_CR21","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1016\/j.ijrobp.2021.12.150","volume":"112","author":"Y Wang","year":"2022","unstructured":"Wang Y, Zhang T, Huang Y, Li W, Zhao J, Yang Y et al (2022) Real-World safety and efficacy of consolidation Durvalumab after chemoradiation therapy for Stage III non-small cell lung cancer: A systematic review and meta-analysis. Int J Radiat Oncol Biol Phys 112(5):1154\u20131164","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"6470_CR22","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/j.ijrobp.2020.05.002","volume":"108","author":"L Yin","year":"2020","unstructured":"Yin L, Xue J, Li R, Zhou L, Deng L, Chen L et al (2020) Effect of low-dose radiation therapy on abscopal responses to hypofractionated radiation therapy and Anti-PD1 in mice and patients with non-small cell lung cancer. Int J Radiat Oncol Biol Phys 108(1):212\u2013224","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"6470_CR23","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.663986","volume":"12","author":"Q Zhang","year":"2021","unstructured":"Zhang Q, Tang L, Zhou Y, He W, Li W (2021) Immune checkpoint inhibitor-associated pneumonitis in non-small cell lung cancer: Current understanding in characteristics, diagnosis, and management. Front Immunol 12:663986","journal-title":"Front Immunol"}],"container-title":["Journal of Cancer Research and Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-026-06470-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00432-026-06470-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-026-06470-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T17:07:02Z","timestamp":1785517622000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00432-026-06470-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,10]]},"references-count":23,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,4]]}},"alternative-id":["6470"],"URL":"https:\/\/doi.org\/10.1007\/s00432-026-06470-4","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-8470834\/v1","asserted-by":"object"}]},"ISSN":["1432-1335"],"issn-type":[{"value":"1432-1335","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,10]]},"assertion":[{"value":"29 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was conducted in accordance with the Declaration of Helsinki.This study was waived the need for approval by the Ethics Committee of Shandong First Medical University Affiliated Cancer Hospital\u3002","order":2,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"86"}}